Asunaprevir

Products

Asunaprevir is not currently registered in many countries. It has been approved in Japan since 2014 (Sunvepra, Bristol-Myers Squibb) and is used in combination with daclatasvir (Daklinza) as an interferon and ribavirin-free treatment.

Structure and properties

Asunaprevir (C₃₅H₄₆ClN₅O₉S, M_r = 748.3 g/mol)

Effects

Asunaprevir has antiviral properties. The effects are due to selective and competitive binding to the NS3/4A protease complex. HCV NS3 serine protease is an enzyme involved in viral replication.

Indications

For the treatment of chronic hepatitis C (combination therapy).